Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Prevalence of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide
7 evidence topics · 6 sources
U.S. prevalence in 2023, all prostate cancer stages
Modeled U.S. prevalence of metastatic castration-resistant prostate cancer by clinical state, 2009 and 2020
| Clinical state | Prevalence, 2009 | Prevalence, 2020 projection |
|---|---|---|
| Asymptomatic or minimally symptomatic mCRPC not treated with or not progressed on chemotherapy | “6745”View highlighted excerpt for this quote | “8320”View highlighted excerpt for this quote |
| Symptomatic mCRPC not treated with or not progressed on chemotherapy | “32,145”View highlighted excerpt for this quote | “39,650”View highlighted excerpt for this quote |
| mCRPC that progressed on or after first-line chemotherapy | “23,220”View highlighted excerpt for this quote | “28,720”View highlighted excerpt for this quote |
Metastatic disease among men living with prostate cancer, modeled U.S. estimate for 2009
Prior androgen receptor pathway inhibitor before metastatic castration-resistant prostate cancer, U.S. Flatiron cohort 2016 to 2023
“Before mCRPC diagnosis, most patients (73.9% [3963/5361]) had not received treatment intensification; 867 (16.2%) had received prior ARPi only; 448 (8.4%), prior taxane only; and 83 (1.5%), both prior ARPi and taxane.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The use of ARPi-only treatment before mCRPC diagnosis rose from 10.3% in 2018 to 34.8% in 2023.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Over the study course, the majority (76.8%) of patients received an ARPi as 1L treatment for mCRPC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prior abiraterone for metastatic hormone-sensitive disease and androgen receptor pathway inhibitor reuse, U.S. ConcertAI cohort 2020 to 2023
“Among 609 people identified, the most common prior treatment for mHSPC was androgen deprivation therapy (ADT) alone (53%); others included ADT plus abiraterone (ABI; 19%), ADT plus a non-ABI androgen receptor pathway inhibitor (ARPI; 18%) and ADT plus docetaxel (10%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among those who received ADT plus ABI or a non-ABI ARPI for mHSPC, 50% and 40%, respectively, also received an ARPI 1L for mCRPC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prior novel hormonal therapy and sequential novel hormonal therapy, Medicare fee-for-service cohort 2014 to 2019
“Ten per cent of patients had undergone NHT use prior to their mCRPC diagnosis, and 3% had previously been treated with taxane-based chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common 1 L to 2 L treatment sequences among men with ≥2 lines were NHT followed by a different NHT (33%), chemotherapy followed by NHT (14%), and NHT followed by chemotherapy (13%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote